| Alemtuzumab (Campath) | CD52 | Humanized, unconjugated | Chronic lymphocytic leukemia | Hematologic toxicity; opportunistic infections; rash | CBC; CD4 counts |
| Live vaccines should be avoided |
| Herpes and Pneumocystis prophylaxis recommended |
| Bevacizumab (Avastin) | VEGF | Humanized, unconjugated | Colorectal cancer, non-small cell lung cancer (nonsquamous) | Gastrointestinal perforation; wound healing complications; hemorrhage; arterial and venous thromboembolism; proteinuria; hypertension | Urinalysis; blood pressure |
| Discontinue use several weeks before elective surgery; do not restart until surgical incision has healed |
| Cetuximab (Erbitux) | EGFR | Chimeric, unconjugated | Colorectal cancer, head and neck cancers | Acneiform rash; diarrhea; hypomagnesemia; nausea and vomiting; interstitial lung disease (rare) | Electrolyte levels; signs of inflammatory and infectious sequelae in patients with dermatologic toxicity; signs of pulmonary toxicity |
| Gemtuzumab Ozogamicin (Mylotarg) | CD33 | Humanized, toxin conjugate (calicheamicin) | Acute myeloid leukemia | Severe myelosuppression; hepatotoxicity | CBC; electrolyte levels; liver chemistries |
| 90Y-Ibritumomab Tiuxetan (Zevalin) | CD20 | Murine, radioisotope conjugate (yttrium-90) | Non-Hodgkin's lymphoma | Severe, prolonged myelosuppression; severe mucocutaneous reactions (e.g., Stevens-Johnson syndrome); risk of secondary malignancies (e.g., acute myeloid leukemia) | CBC; pretreatment antibody titers in patients who have received other murine-based radioimmunotherapy regimens |
| Radiation safety precautions required for one week after administration* |
| Panitumumab (Vectibix) | EGFR | Human, unconjugated | Colorectal cancer | Acneiform rash; diarrhea; hypomagnesemia; hypocalcemia; nausea and vomiting; interstitial lung disease (rare) | Electrolyte levels; signs of inflammatory and infectious sequelae in patients with dermatologic toxicity; signs of ocular toxicity (e.g., conjunctivitis, ocular hyperemia, increased lacrimation, eye or eyelid irritation) |
| Rituximab (Rituxan) | CD20 | Chimeric, unconjugated | Non-Hodgkin's lymphoma, rheumatoid arthritis | Lymphocytopenia; HBV reactivation; severe mucocutaneous reactions (e.g., Stevens-Johnson syndrome) | CBC; signs of active HBV infection or hepatitis in patients who are HBV carriers |
| Live vaccines should be avoided |
| 131I-Tositumomab (Bexxar) | CD20 | Murine, radioisotope conjugate (iodine-131) | Non-Hodgkin's lymphoma | Hypothyroidism; severe, prolonged myelosuppression; nausea and vomiting; secondary malignancies (e.g., acute myeloid leukemia) | CBC; thyroid function tests; pretreatment antibody titers in patients who have received other murine-based radioimmunotherapy regimens |
| Radiation safety precautions required for one week after administration* |
| Trastuzumab (Herceptin) | HER2/neu | Humanized, unconjugated | Breast cancer with HER2/neu overexpression | Cardiomyopathy (especially if coadministered with anthracycline chemotherapy); cytopenias; rash | Electrocardiography; left ventricular ejection fraction |